Skip to content
Companies

Lycia Therapeutics

Extracellular protein degraders for immune diseases

Raised to date

$75M

of $75M offered across 1 Form D filing

Investors
16
Last filed
Jun 25, 2026

About

Lycia Therapeutics is a South San Francisco biotechnology company developing targeted protein degradation therapeutics aimed at the extracellular proteome. Its LYTAC (lysosomal targeting chimera) platform is built on research from Nobel laureate Carolyn Bertozzi and works by binding a disease-causing secreted or transmembrane protein and trafficking it into the cell for lysosomal degradation. The company is advancing programs in autoimmune, allergic and inflammatory disease and raised a $106.6 million Series C in May 2024 led by Venrock Healthcare Capital Partners.

Most protein degraders act only on intracellular targets; Lycia's LYTAC and CataLYTAC modalities reach the extracellular proteome — secreted proteins and cell-surface receptors, including pathogenic autoantibodies — that has been largely undruggable by degradation approaches.

Funding

  • EquityFiled Jun 25, 2026Form D
    $75M/ $75M

Product

LYTAC platform

Drug discovery platform

A lysosomal-targeting-chimera drug discovery platform that generates bifunctional molecules which bind an extracellular target protein and shuttle it into the lysosome for degradation, plus a catalytic variant the company calls CataLYTAC.

  • Degrades extracellular and transmembrane proteins rather than merely inhibiting them
  • CataLYTAC catalytic degrader modality
  • Antigen-specific autoantibody degradation for autoimmune disease

Built for

Patients with autoimmune, allergic and inflammatory diseases, reached through prescribing physicians and pharmaceutical partners; the company's near-term counterparties are biopharma collaborators and healthcare investors

People on file